Related Experiment Video
Updated: Jul 13, 2026
Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
Published on: November 17, 2023
Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer
Carsten Stephan1, Hellmuth-Alexander Meyer, Eva-Maria Paul
1Departments of Neurology, Universitätsmedizin Charité Berlin, CCM, Germany. carsten.stephan@charite.de
Background:
ProPSA has been suggested for the detection of preferentially aggressive prostate cancer (PCa). We report on the use of proPSA and free PSA to enhance preoperative staging and grading.
Patients And Methods:
Serum samples from 376 PCa patients within the PSA range 1-25 microg/l who underwent radical prostatectomy were analysed for PSA, free PSA (fPSA) and (-5, -7) proPSA.
Results:
ProPSA was only significantly different between pT2 and pT3 PCa (p = 0.02) in the subgroup of patients with % fPSA < 10%. The ratio proPSA/% fPSA differed between G2 and G3 (p = 0.004), Gleason < 7 and Gleason > or =7 (p = 0.001), and pT2 and pT3 tumors (p < 0.0001) at PSA 1-25 microg/l. However, % fPSA improved differentiation only between Gleason < 7 and Gleason > or = 7 tumors, not between pT2 and pT3 or G2 and G3 tumors.
Conclusion:
ProPSA as a single parameter did not improve the detection of non-organ confined or aggressive PCa whereas proPSA/% fPSA further improved staging and grading within all analysed PSA ranges.
